Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease
Development of indole-3-propionic acid (OXIGON™) for Alzheimer's disease
复制标题
DOI：
10.1007/s12031-002-0036-0
复制
发表时间：
2002-08-01
影响因子：
3.1
通讯作者：
Chain, DG
中科院分区：
文献类型：
--
作者：
Bendheim, PE;Poeggeler, B;Chain, DG
淀粉样蛋白β的积累和伴随的氧化应激是阿尔茨海默病的主要致病事件。吲哚-3-丙酸（IPA，OXIGON（TM））是一种没有促氧化活性的有效抗氧化剂。IPA已被证明是β-淀粉样蛋白原纤维形成的抑制剂，并且是针对多种氧化毒素的有效神经保护剂。本文将总结IPA的已知特性，并概述其选择作为阿尔茨海默病潜在的疾病修饰疗法的基本原理。
The accumulation of amyloid-beta and concomitant oxidative stress are major pathogenic events in Alzheimer's disease. Indole-3-propionic acid (IPA, OXIGON(TM)) is a potent anti-oxidant devoid of pro-oxidant activity. IPA has been demonstrated to be an inhibitor of beta-amyloid fibril formation and to be a potent neuroprotectant against a variety of oxidotoxins. This review will summarize the known properties of IPA and outline the rationale behind its selection as a potential disease-modifying therapy for Alzheimer's disease.